Physician profile
Prashant A Desai
NPI 1023337722
$2,047.27
in general payments reported to CMS, 2019-2025
28 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $551 · 2021: $171 · 2022: $15.88 · 2023: $36.38 · 2024: $34.39 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $603.13 | 2020-2025 | Optune, Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $226.23 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $147.61 | 2025 | Oxford |
| Astrazeneca Pharmaceuticals LP | $139.62 | 2020-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $126.70 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $101.48 | 2019-2025 | |
| Janssen Biotech, INC. | $99.29 | 2025 | Rybrevant, Balversa, Erleada |
| Incyte Corporation | $75.39 | 2025 | Monjuvi, Zynyz |
| Myovant Sciences INC. | $54.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.81 | 2025 | Fruzaqla, Vpriv |
| Tersera Therapeutics LLC | $38.60 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $38.26 | 2025 | Datroway, Vanflyta |
| Eisai INC. | $30.86 | 2025 | |
| Tolmar, INC. | $28.56 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $28.56 | 2025 | Rubraca |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $26.16 | 2025 | Rytelo |
| Immunocore Limited | $25.47 | 2025 | Kimmtrak |
| Blue Earth Diagnostics | $24.99 | 2019 | |
| Siemens Medical Solutions USA, INC. | $24.07 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.97 | 2025 | |
| Emd Serono, INC. | $20.62 | 2025 | |
| Ge Healthcare | $20.26 | 2021 | |
| Adaptive Biotechnologies Corporation | $18.69 | 2025 | Clonoseq |
| Tactile Systems Technology INC | $17.38 | 2021 | |
| Sumitomo Pharma America, INC. | $16.68 | 2023 | Orgovyx |
| Servier Pharmaceuticals LLC | $16.41 | 2025 | |
| Genzyme Corporation | $14.98 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.